ENDRA Life Sciences (NASDAQ:NDRA) Research Coverage Started at HC Wainwright

HC Wainwright initiated coverage on shares of ENDRA Life Sciences (NASDAQ:NDRA) in a report issued on Monday morning, Benzinga reports. The firm issued a buy rating and a $6.00 target price on the stock.

Several other research analysts have also issued reports on the stock. Dougherty & Co initiated coverage on shares of Tactile Systems Technology in a report on Thursday, June 13th. They set a buy rating and a $80.00 price target for the company. Lake Street Capital initiated coverage on shares of ENDRA Life Sciences in a report on Monday, May 20th. They set a buy rating for the company.

ENDRA Life Sciences stock opened at $1.46 on Monday. ENDRA Life Sciences has a 52-week low of $0.90 and a 52-week high of $5.75. The stock’s 50 day moving average price is $1.48.

ENDRA Life Sciences (NASDAQ:NDRA) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.37) earnings per share (EPS) for the quarter. On average, sell-side analysts forecast that ENDRA Life Sciences will post -1.03 earnings per share for the current year.

In related news, insider Michael Milos Thornton acquired 30,000 shares of ENDRA Life Sciences stock in a transaction dated Thursday, May 16th. The stock was bought at an average price of $1.13 per share, with a total value of $33,900.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 11.40% of the company’s stock.

A hedge fund recently bought a new stake in ENDRA Life Sciences stock. Geode Capital Management LLC acquired a new position in shares of ENDRA Life Sciences Inc (NASDAQ:NDRA) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 47,760 shares of the company’s stock, valued at approximately $71,000. Geode Capital Management LLC owned 0.72% of ENDRA Life Sciences as of its most recent SEC filing. Institutional investors and hedge funds own 17.17% of the company’s stock.

About ENDRA Life Sciences

ENDRA Life Sciences Inc develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding.

Featured Article: Commodities

Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.